Research Article

Glycoprotein IIb/IIIa and P2Y\textsubscript{12} Induction by Oligochitosan Accelerates Platelet Aggregation

Mercy Halleluyah Periayah,\textsuperscript{1} Ahmad Sukari Halim,\textsuperscript{1} Nik Soriani Yaacob,\textsuperscript{2} Arman Zaharil Mat Saad,\textsuperscript{1} Abdul Rahim Hussein,\textsuperscript{3} Ahmad Hazri Abdul Rashid,\textsuperscript{4} and Zanariah Ujang\textsuperscript{4}

\textsuperscript{1} Reconstructive Sciences Unit, School of Medical Sciences, Universiti Sains Malaysia, 16150 Kubang Kerian, Kelantan, Malaysia
\textsuperscript{2} Department of Chemical Pathology, School of Medical Sciences, Universiti Sains Malaysia, 16150 Kubang Kerian, Kelantan, Malaysia
\textsuperscript{3} Advanced Medical & Dental Institute, Universiti Sains Malaysia, No. 1-8, Persiaran, Sekyen 4/1, Bandar Putra Bertam, 13200 Kepala Batas, Pulau Pinang, Malaysia
\textsuperscript{4} Industrial Biotechnology Research Centre, SIRIM Berhad, No. 1 Persiaran Dato’ Menteri, Section 2, P.O. Box 7035, 40700 Shah Alam, Selangor, Malaysia

Correspondence should be addressed to Ahmad Sukari Halim; ashalim@usm.my

Received 23 May 2014; Accepted 21 July 2014; Published 28 August 2014

Academic Editor: Saulius Butenas

Copyright © 2014 Mercy Halleluyah Periayah et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Platelet membrane receptor glycoprotein IIb/IIIa (gpiibiiia) is a receptor detected on platelets. Adenosine diphosphate (ADP) activates gpiibiiia and P2Y\textsubscript{12}, causing platelet aggregation and thrombus stabilization during blood loss. Chitosan biomaterials were found to promote surface induced hemostasis and were capable of activating blood coagulation cascades by enhancing platelet aggregation. Our current findings show that the activation of the gpiibiiia complex and the major ADP receptor P2Y\textsubscript{12} is required for platelet aggregation to reach hemostasis following the adherence of various concentrations of chitosan biomaterials [7% N,O-carboxymethylchitosan (NO-CMC) with 0.45 mL collagen, 8% NO-CMC, oligochitosan (O-C), and oligochitosan 53 (O-C53)]. We studied gpiibiiia and P2Y\textsubscript{12} through flow cytometric analysis and western blotting techniques. The highest expression of gpiibiiia was observed with Lyostypt (74.3 ± 7.82%), followed by O-C (65.5 ± 7.17%). Lyostypt and O-C resulted in gpiibiiia expression increases of 29.2% and 13.9%, respectively, compared with blood alone. Western blot analysis revealed that only O-C 53 upregulated the expression of P2Y\textsubscript{12} (1.12 ± 0.03-fold) compared with blood alone. Our findings suggest that the regulation of gpiibiiia and P2Y\textsubscript{12} levels could be clinically useful to activate platelets to reach hemostasis. Further, we show that the novel oligochitosan is able to induce the increased expression of gpiibiiia and P2Y\textsubscript{12}, thus accelerating platelet aggregation in vitro.

1. Introduction

Platelets, which circulate within the blood, are the essential mediators that trigger the mechanical pathway of the coagulation cascade upon encountering any damage to the blood vessels. Platelets encourage primary hemostasis via three major processes: activation, adhesion, and aggregation. When the integrity of the vascular endothelium is interrupted, various macromolecular elements of the vascular subendothelium become exposed and readily accessible to platelets \cite{1}. Platelet membrane receptor glycoprotein IIb/IIIa (gpiibiiia), also known as α\textsubscript{IIb}β\textsubscript{3}, is an integrin complex and fibrinogen receptor that is detected on platelets. This integrin complex is essential for platelet aggregation and for platelet adherence to the endothelium, organized through the calcium-dependent association of gpIIb and gpIIIa \cite{2–4}. Upon receptor activation, adenosine diphosphate (ADP) plays a vital role in modulating platelet function. The induction of platelet aggregation through the effective stimulation of 2 major ADP receptors (P2Y\textsubscript{1} and P2Y\textsubscript{12}) has been well documented \cite{5, 6}. In blood loss phenomena, ADP activates gpiibiiia and P2Y\textsubscript{12}, causing platelet aggregation and thrombus stabilization by recruiting more circulating platelets to the vessel injury to regulate adhesion. Biologically
active hemostatic agents and sealants are used to stop hemorrhage by promoting hemostasis at sites of vascular injury. There is a large volume of published studies describing the role of hemostatic agents in assisting platelet mediators to expedite the mechanisms of hemostasis. In the new global economy, debate continues regarding the best strategies for the management of hemorrhage within the needed period of time. Chitosan biomaterials, which are extracted from marine arthropods, were found to promote surface-induced hemostasis and to be capable of activating blood coagulation cascades. Chitosan biomaterials have mainly been noticed because they function independently on platelets rather than abiding by normal clotting pathways. Chitosan is composed of an aminopolysaccharide molecule that possesses a strong positive charge, strongly attracting and bonding to negatively charged molecules [7–9]. However, the scientific evidence from the last decades on the mechanical pathways of platelet-specific behavior upon the adherence of chitosan-derived biomaterials remains controversial and unclear. Many studies have emphasized the prominent benefit of chitosan-derived biomaterials, elucidating promising outcomes towards efficiently altering platelet activities. In contrast, no research thus far has reviewed the role of gpibniia and P2Y12 mediators in assisting platelet adhesion and aggregation. As a consequence, we have designed a study to determine the significant involvement of chitosan biomaterials on the expression of these mediators in expediting the process of hemostasis. In our present work, we tested N,O-carboxymethylchitosan (NO-CMC) and oligochitosan (O-C), chitosans produced by the Standard and Industrial Research Institute of Malaysia (SIRIM Berhad) with a degree of deacetylation of 75–98%. Our results demonstrated the ability of chitosan-based hemostatic agents to induce the potentiality of intracellular signaling cascades that involve the release of gpibniia and P2Y12 upon the possible stimulation of platelet activity by chitosan bioadhesives.

2. Materials and Methods

2.1. Biomaterials. Chitosan sponges with variable chitosan formulations (7% NO-CMC with 0.45 mL collagen, 8% NO-CMC, O-C, and a powdered variety of chitosans termed O-C 53) were used. Lyostypt was used as the positive control.

2.2. Reagents. Antibodies (Ab) s for flow cytometry were purchased from Becton Dickinson (BD, NJ, USA): anti-CD 61 (integrin beta 3 chain), PerCP (clone RUU-PL 7F12 hybridization of mouse P3X63.Ag8.653 myeloma cells with spleen cells from BALB/c mice immunized with purified platelet membrane glycoproteins) (CD61 PerCP (340506)), and a fluorescein isothiocyanate- (FITC-) conjugated monoclonal antibody to CD41a (clone HIP8, derived from hybridization of mouse P3X63 myeloma cells with spleen cells from BALB/c mice immunized with purified platelet membrane glycoprotein) (CD41a FITC (340929)). All Abs for western blotting were purchased from Abcam (England, UK): (primary antibodies (1'): anti-P2Y12 Ab (rabbit polyclonal to P2Y12) (ab82725), dilution 1:1000; anti-beta actin (rabbit polyclonal to beta-actin-loading control) (ab8227), dilution 1:2000; and secondary antibody (2'): chicken polyclonal secondary Ab to rabbit IgG-H&L (HRP) (ab6829), dilution 1:2000). The Aurum serum protein mini kit and protein standards and ladder for SDS-PAGE (Precision Plus Protein Western Standards Value Pack) were purchased from BioRad (USA). The enhanced chemiluminescence detection kit (Amersham ECL Select western blotting detection reagent) was purchased from GE Healthcare life sciences (UK).

2.3. Flow Cytometry

2.3.1. Blood Collection. Twelve milliliters of whole blood was drawn by venipuncture from 14 healthy donors into 4.5 mL Vacutainer tubes containing 3.2% buffered sodium citrate anticoagulant (REF 363083) using a butterfly needle. Blood was obtained with written informed consent. Prior to commencing the study, ethical clearance was obtained from the Human Ethics Committee of Universiti Sains Malaysia (USM). None of the female donors were taking oral contraceptives at the time of collection. None of the healthy donors had been diagnosed with chronic diseases. Subject selection was contingent upon a hematocrit level between 38% and 45% and a normal platelet count between 150 × 10⁹/μL and 350 × 10⁹/μL. To evaluate gpibniia expression, three-way stopcocks were used to collect blood under minimal tourniquet pressure, and the first 1 mL of blood withdrawn was discarded to minimize tissue factor-induced activation. The remainder of each blood sample was aliquoted into 3 tubes containing 3.2% sodium citrate.

2.3.2. Sample Preparation. Freshly drawn blood was subjected to centrifugation at 100 g at room temperature (20–25°C) for 15 min [10]. Chitosan samples, each weighing 10 mg, were dissolved in 50 μL of phosphate-buffered saline (PBS) (pH 7.4) and subjected to incubation at 37°C for 60 min. One hundred microliters of platelet-rich plasma (PRP) was then mixed with each prepared chitosan sample for 30 min [11–13]. Ten microliters of PRP was aliquoted in two different FACs tubes; the first tube contained unstained cells, and the second tube was incubated with CD61 PerCP (340506) and CD41a FITC (340929) (BD, USA). Stained and unstained cells were incubated in a dark at room temperature for 10 min. The reaction was stopped with 500 μL of cold FACs buffer. Samples were analyzed immediately or kept at 4°C and analyzed within 24 hours. The expression of gpibniia was analyzed using flow cytometry.

2.3.3. Analysis of Platelets with Flow Cytometry. Flow cytometric measurements of platelets were performed with the FACS Canto II (Becton-Dickinson Bioscience, USA) flow cytometer. The process of sample analysis prior to flow cytometric analysis is fundamentally comprised of five major steps: (1) chitosan-adhered blood sample preparation; (2) flow cytometer system and reagent setup; (3) cell fixation process; (4) cell permeabilization and immunolabeling; and (5) fluorescent staining and platelet counterstaining. A polygonal gate was created to propose each dot plot pattern. Four regions were proposed and labeled Q1, Q2, Q3, and Q4.
The quadrants represent positivity for the following markers: Q1: CD 41a FITC-A; Q2: CD 41a FITC-A and CD61 PerCP-A; Q3: unstained/instrument noise; and Q4: CD61 PerCP-A within the gpiibIIa-positive population. At least 10,000 events were analyzed to calculate the mean fluorescence intensity (MFI) (%) of the total platelet population. The detectors were set to logarithmic amplification. The acquisition and data interpretation were accomplished using BD FACS Diva software.

2.4. Western Blotting

2.4.1. Blood Sample Collection and Preparation. Blood sample collection procedures were carried out as described above. The Aurum serum protein mini kit (Bio-Rad, USA) was used to maximize the resolution of major ADP receptor P2Y12 expression using western blotting techniques. Sample preparation consists of 3 major steps: (1) column setup; (2) sample binding and purification; and (3) collection of purified samples. Purified chitosan-treated samples were then subjected to a protein quantification test.

2.4.2. Protein Quantification. Two microliters of purified chitosan-treated samples was added to measure protein quantity (mg/mL). Protein concentrations were determined using a NanoDrop 2000 UV-Vis Spectrophotometer (Thermo Fisher Scientific) at 280 nm absorbance.

2.4.3. Western Blot Analysis. One hundred nanograms of protein was resolved on a 10% SDS-Polyacrylamide gel for 45 min followed by semidry transfer onto a Nitrocellulose membrane using the Trans-Blot SD semidry transfer cell (Bio-Rad, USA). The membrane was then blocked with 5% nonfat milk diluted in PBS-Tween 20 for 2 hours at RT under mild agitation. The membrane was then washed with 1X PBS for 10 min × 4 times and incubated with the 1’ Ab (P2Y12 or β-actin Ab) in blocking buffer overnight at 4°C. On the following day, the incubated membrane was washed with PBS-Tween 20 (0.001%) for 10 min × 4 times. The washed membrane was then incubated with the 2’ Ab conjugated to horseradish peroxidase in blocking buffer for 2 hours at RT. Then, the membrane was again washed with PBS-Tween 20 for 10 min × 4 times. The membrane was developed with the enhanced chemiluminescence detection system using FluorChem FC2 (USA), and analyses were conducted using AlphaView Software. The band density for each test was compared to the control—the bands were analyzed using ImageJ 1.46 software (provided by NIH (http://imagej.nih.gov/ij/)), and values were normalized to the β-actin band density [14, 15].

2.5. Statistical Analysis. The data are presented as percentages for gpiibIIa analysis (n = 14). Three independent experiments were carried out to demonstrate the expression of P2Y12. An independent t-test was applied to elucidate the mean ± standard error of mean (SEM) and the significance value of the expression levels. Statistical significance was defined as P ≤ 0.05, and these values were calculated using SPSS software, version 18.0.

3. Results

3.1. Expression of gpiibIIa. The mean fluorescence intensity of the total platelet populations was calculated from at least 10,000 events, in percentages. A polygonal gate was created to propose each dot plot pattern. Four regions were proposed and labeled Q1, Q2, Q3, and Q4. Each quadrant represents the following: Q1: CD 41a FITC-A; positive for gpiib; Q2: CD 41a FITC-A and CD61 PerCP-A; positive for gpiibIIa; Q3: unstained/instrument noise; and Q4: CD61 PerCP-A; positive for gpiia. The percentage of platelets expressing gpiibIIa upon flow cytometric analysis ranged from 0.5% to 99.3%. The highest expression of gpiibIIa was observed with Lyostypt (74.3 ± 7.82%), followed by O-C (65.5 ± 7.17%). Lyostypt and O-C resulted in increases of 29.2% and 13.9%, respectively, compared with blood alone (P < 0.05). On the contrary, gpiibIIa was expressed at the lowest relative levels upon the adherence of two different types of NO-CMCs, which were 5.90 ± 0.77% for 7% NO-CMC and 7.74 ± 1.40% for 8% NO-CMC. O-C induced either a slight increase or equivalent expression levels compared with the blood alone. Chitosan stimulation of gpiibIIa expression varied between each donor (n = 14) (P < 0.05) (Figure 1).

The example of the dot plot results for the tested biomaterials presented in Figure 2 (CD 41a FITC-A × CD 61 PerCP-A) shows the population positive for gpiibIIa. The Q2 region is positive for gpiibIIa expression (values are presented as percentages and highlighted in red). As mentioned, the expression levels following the adherence of 7% NO-CMC and 8% NO-CMC correlated with the low percentages. The O-C chitosan group expressed gpiibIIa at equivalent levels but 6-fold greater percentages than NO-CMCs (Figures 2(a)–2(d)). As for the overall outcome, O-C induced the expression of gpiibIIa and functioned equivalently to blood alone (Figure 2(f)). Therefore, O-C was considered to...
Figure 2: Continued.
work effectively as a bioadhesive material to induce gpIIbIIa expression and to promote platelet aggregation to achieve hemostasis in vitro.

3.2. **P2Y₁₂ Expression.** We have investigated the expression of P2Y₁₂ receptor signaling upon the adherence of bioadhesive chitosan biomaterials, which aid in platelet adhesion and thrombus formation. Western blot analysis (n = 3) revealed that O-C 53 was capable of upregulating the expression of P2Y₁₂ by 1.12 ± 0.03-fold when compared with blood alone. Additionally, Lyostypt, the commercially available hemostatic agent used as positive control, was capable of inducing the upregulation of P2Y₁₂ by 1.11 ± 0.04-fold. On the contrary, the remaining chitosan biomaterials tested downregulated the expression of P2Y₁₂, as follows: O-C with a 0.94 ± 0.05-fold change; 7% NO-CMC with a 0.87 ± 0.04-fold change; and 8% NO-CMC with a 0.87 ± 0.06-fold change. The dotted line in Figure 2 depicts the expression level in the blood alone, which we fixed to 1 when calculating the band densities in ImageJ. Although the fold changes observed are very close for each biomaterial, O-C 53 exclusively induced the highest fold-change in expression.

4. **Discussion.**

Platelets are the first-line fundamental elements that support the maintenance of hemostasis. This mechanical system arrests blood loss whenever there is an injury to the vessel wall. Hemostasis is triggered by 3 major pathogenic events: platelet activation, adhesion, and aggregation [16]. Platelet aggregation requires the engagement of platelets via physical forces once platelets are activated by the adherence of any antihemorrhagic biomaterials. However, fibrin formation occurs due to chemical synthesis of fibrin polypeptides through the actions of enzymes and cofactors. Platelet aggregation is mediated by the gpIIbIIa receptor, which was discovered to be one of the abundant cell surface receptors (80 × 10³ per platelet) and represents 15% of total surface proteins [17, 18]. Over the past years, ADP and gpIIbIIa receptors have been targeted for antithrombotic strategies with drug compounds, such as ticlopidine, clopidogrel, abciximab, eptifibatide, and tirofiban, as alternative therapies to reduce vascular complications [19]. Chitosan-derived hemostatic agents are capable of activating platelets by providing a good surface for blood coagulation mediators and signals to facilitate thrombin generation, which is then able to stimulate gpIIbIIa activation. Thrombin is one of the blood coagulation factors,
and the presence of thrombin suggests the existence of clots. A large number of researchers have successfully investigated chitosan biomaterials in blood coagulation, either by chitosan alone or fabricated with other naturally obtained polymers, due to their prominent biodegradable, biocompatible, nontoxic, and antihemorrhagic properties. Studies have been proposed that chitin and chitosan have specific properties based on their solubility in aqueous acetic acid, as chitosan is soluble, but chitin is insoluble. Thermal intervention and modification of chitin under firm aqueous alkali are normally required to provide partially deacetylated chitin (30–90%), which is then considered chitosan. Deacetylation (DA) is a process that releases the amine groups (NH2), generating chitosan with cationic characteristics. The percentage of DA was given more careful thought while preparing chitosan due to the influence of the acidic environment, whereas the majority of polysaccharides appears to be neutral or negatively charged [20–22]. Although the importance of chitin was first described in 1811 by Henri Braconnot and has been highlighted over the years, chitosan has recently taken a central role in solving many medical difficulties in the new global economy [23].

Our present paper generated information regarding the activation of the gpiibiiia complex and ADP major receptor P2Y12, required for platelet aggregation to complete the hemostasis process, upon the adherence of various concentrations of chitosan biomaterials produced by SIRIM Berhad, with DA values <85% and molecular weights <40000 Da. Additionally, no studies thus far have reviewed the role of gpiibiiia and P2Y12 mediators in assisting platelet adhesion and aggregation in the presence of chitosan-derived biomaterials. We have utilized two different markers (CD 41a FITC-A and CD 61 PerCP-A) to detect the expression of gpiibiiia on platelets. CD41/CD61 is a complex composed of noncovalently associated CD41 and CD61. This complex is derived from a member of the integrin family primarily expressed on platelets and megakaryocytes. CD41/CD61 mediates platelet aggregation and platelet adhesion to the extracellular matrix [24–26]. Chitosan stimulation of gpiibiiia expression varies between individuals. Both 7% and 8% NO-CMCs induced low levels of gpiibiiia expression. The O-C group of chitosan resulted in a 6-fold greater percentage of platelets expressing gpiibiiia than NO-CMCs. As for the overall outcome, O-C induced gpiibiiia expression and function equal to blood alone and was considered to work effectively as a biodhesive material to induce gpiibiiia expression and to promote platelet aggregation and hemostasis in vitro. Platelet gpiibiiia is a calcium-dependent receptor that acts with adhesive proteins on the membrane surface of platelets, with the assistance of O-C, to mediate platelet binding to a variety of cells and substrate.

We used 7% NO-CMC that was coated and premixed with 0.45 mL of bovine collagen in predetermined compositions and freeze-dried to obtain a porous structure. The main reason for using collagen-coated chitosan in our study was that collagen is capable of initiating platelet aggregation at sites of tissue injury [7]. Collagen is one of the most abundant proteins and can be extracted from nearly every single living animal. The common resources for the collagen used in tissue engineering and regenerative applications are mainly bovine skin and tendons. Collagen proteins have been shown to play essential roles in platelet adhesion and the acceleration of platelet activation to trigger the increased production of procoagulant phospholipids [27]. Nevertheless, 7% NO-CMC was unable to produce an effective increase in gpiibiiia expression. However, our previous results suggested that 7% NO-CMC was able to recruit platelets and enhance platelet aggregation on porous scaffolds [28]. The exact mechanism that controls the expression of activated gpiibiiia complexes remains unknown [29, 30].

The P2Y12 receptor is a member of the G protein-coupled receptor family and is triggered by ADP to activate various signaling pathways involved in the amplification of platelet activation and aggregation [31]. As highlighted in the results section, we successfully studied the expression of P2Y12 in
the presence of two different classes of chitosan biomaterials via western blotting. Western blot analysis of band densities revealed that O-C 53 upregulated the expression of P2Y12 by 1.12-fold. Moreover, β-actin expression was not influenced or affected by the adherence of chitosan biomaterials to blood proteins throughout the experiments. Although chitosan biomaterials are thought to work in mysterious ways, as the exact mechanical functions have not been revealed, the hemostatic properties of chitosan biomaterials are known to entirely rely on several important aspects, including the molecular weight, degree of deacetylation, solubility, chitosan concentration, positive charge density, chemical structure modification, pH, temperature, incubation period, and hydrophobic and hydrophilic characteristics [32]. However, controversy still exists over the scientific evidence into the mechanical pathways of platelet-specific behavior following the adherence of chitosan-derived biomaterials. Therefore, further study with more focus on the technical aspects of O-C is suggested to show a strong relationship between O-C and platelet mechanisms.

5. Conclusions

Our findings suggest that the analysis of gpibiiia and P2Y12 is clinically useful for platelet activation to reach hemostasis. In the present study, we showed that different chitosan groups with different formulations differentially activate platelet mechanisms. A novel oligochitosan, either in sponge or in powdered form, was able to induce expression levels of gpibiiia and P2Y12 to accelerate platelet aggregation in vitro. The value “53” added to O-C is just a sequence identification figure to distinguish between the sponge and powdered type of chitosans. Despite the considerable amount of work carried out to emphasize the importance of gpibiiia and P2Y12 expression in the presence of chitosan-derived biomaterials, the mechanical pathways of both platelet activities and chitosans remain unclear. A better understanding of how platelet signals are coordinated during stimulation with chitosan biomaterials is necessary to clarify the mechanism of chitosan-mediated hemostasis.

Conflict of Interests

The authors declare that they have no conflict of interests.

Acknowledgments

The present study was supported by the establishment of a Research University (RU) Grant from University Sains Malaysia (USM) (no. 1001/PPSP/813068). The authors’ research team also would like to extend their appreciation and gratitude to all of the donors who participated in their study.

References

[1] T. Nakamura, J. Kambayashi, M. Okuma, and N. N. Tandon, “Activation of the GP IIb-IIIa complex induced by platelet adhesion to collagen is mediated by both α2β1 integrin and GP VI,” The Journal of Biological Chemistry, vol. 274, no. 17, pp. 11897–11903, 1999.
[2] J. D. Vickers, “Binding of polymerizing fibrin to integrin α(IIb)β3 on cryomatrix-treated rabbit platelets decreases phosphatidylinositol 4,5-bisphosphate and increases cytoskeletal actin,” Platelets, vol. 10, no. 4, pp. 228–237, 1999.
[3] J. J. Calvete, “On the structure and function of platelet integrin α(IIb)β3, the fibrinogen receptor,” Proceedings of the Society for Experimental Biology and Medicine, vol. 208, no. 4, pp. 346–360, 1995.
[4] S. J. Shattil, “Signaling through platelet integrin αIIb β3: Inside-out, outside-in, and sideways,” Thrombosis and Haemostasis, vol. 82, no. 2, pp. 318–325, 1999.
[5] C. Gachet, “ADP receptors of platelets and their inhibition,” Thrombosis and Haemostasis, vol. 86, no. 1, pp. 222–232, 2001.
[6] S. P. Kunapuli, R. T. Dorsam, S. Kim, and T. M. Quinton, “Platelet purinergic receptors,” Current Opinion in Pharmacology, vol. 3, no. 2, pp. 175–180, 2003.
[7] R. Seda Tiğli, A. Karakeçilı, and M. Gumusderelioglu, “In vitro characterization of chitosan scaffolds: Influence of composition and deacetylation degree,” Journal of Materials Science: Materials in Medicine, vol. 18, no. 9, pp. 1665–1674, 2007.
[8] B. Biagini, R. A Muzzarelli, R. Giardino et al., “Biological materials for wound healing,” in Advances in Chitin and Chitosan, C. J. Brine, P.A. Sandford, and J. P. Zikakis, Eds., pp. 16–24, Elsevier Application Science, New York, NY, USA, 1992.
[9] J. Zhang, W. Xia, P. Liu et al., “Chitosan modification and pharmaceutical/biomedical applications,” Marine Drugs, vol. 8, no. 7, pp. 1962–1987, 2010.
[10] K. Peter, B. Kohler, A. Straub et al., “Flow cytometric monitoring of glycoprotein IIb/IIIa blockade and platelet function in patients with acute myocardial infarction receiving reteplase, abciximab, and ticlopidine: continuous platelet inhibition by the combination of abciximab and ticlopidine,” Circulation, vol. 102, no. 13, pp. 1490–1496, 2000.
[11] J. L. Ritchie, H. D. Alexander, and I. M. Rea, “Flow cytometry analysis of platelet P-selectin expression in whole blood—Methodological considerations,” Clinical and Laboratory Haematology, vol. 22, no. 6, pp. 359–363, 2000.
[12] M. Zhou, J. Yang, X. Ye et al., “Blood platelets behavior on nanostuctured superhydrophobic surface,” Journal of Nano Research, vol. 2, pp. 129–136, 2008.
[13] Y. Okamoto, R. Yano, K. Miyatake, I. Tomohiro, Y. Shigemasa, and S. Minami, “Effects of chitin and chitosan on blood coagulation,” Carbohydrate Polymers, vol. 53, no. 3, pp. 337–342, 2003.
[14] I. Ahmad, H. Jimenez, N. S. Yaacob, and N. Yusuf, “Tualang honey protects keratinocytes from ultraviolet radiation-induced inflammation and DNA damage,” Photochemistry and Photobiology, vol. 88, no. 5, pp. 1198–1204, 2012.
[15] N. S. Yaacob and N. E. Ismail, “Comparison of cytotoxicity and genotoxicity of 4-hydroxytamoxifen in combination with Tualang honey in MCF-7 and MCF-10A cells,” BMC Complementary and Alternative Medicine, vol. 14, no. 106, 2014.
[16] B. S. Collier, “Augmentation of thrombolysis with antiplatelet drugs: Overview,” Coronary Artery Disease, vol. 6, no. 12, pp. 911–914, 1995.
[17] C. L. Wagner, M. A. Mascelli, D. S. Neblock, H. F. Weisman, B. S. Collier, and R. E. Jordan, “Analysis of GP1Iib/IIIa receptor number by quantification of 7E3 binding to human platelets,” Blood, vol. 88, no. 3, pp. 907–914, 1996.
[18] L. K. Jennings and D. R. Phillips, “Purification of glycoproteins IIb and III from human platelet plasma membranes and characterization of a calcium-dependent glycoprotein IIb-III complex,” *Journal of Biological Chemistry*, vol. 257, no. 17, pp. 10458–10466, 1982.

[19] B. S. Coller, “Anti-GPIIb-IIIa drugs: current strategies and future directions,” *Thrombosis and Haemostasis*, vol. 86, no. 1, pp. 427–443, 2001.

[20] H. K. No and S. P. Meyers, “Preparation of chitin and chitosan,” in *Chitin Handbook*, R. A. A. Muzzarelli and M. G. Peter, Eds., pp. 475–489, European Chitin Society, Grottammare, Italy, 1997.

[21] W. A. Bough, W. L. Salter, A. C. M. WU, and B. E. Perkins, “Influence of manufacturing variables on the characteristics and effectiveness of chitosan products. I. Chemical composition, viscosity, and molecular-weight distribution of chitosan products,” *Biotechnology and Bioengineering*, vol. 20, no. 12, pp. 1931–1943, 1978.

[22] H. K. No, K. S. Lee, and S. P. Meyers, “Correlation between physicochemical characteristics and binding capacities of chitosan products,” *Journal of Food Science*, vol. 65, no. 7, pp. 1134–1137, 2000.

[23] S. S. Koide, “Chitin-chitosan: properties, benefits and risks,” *Nutrition Research*, vol. 18, no. 6, pp. 1091–1101, 1998.

[24] L. K. Denzin, C. Hammond, and P. Cresswell, “HLA-DM interactions with intermediates in HLA-DR maturation and a role for HLA-DM in stabilizing empty HLA-DR molecules,” *The Journal of Experimental Medicine*, vol. 184, no. 6, pp. 2153–2165, 1996.

[25] J. M. Ribergy, R. R. Arva, H. J. Geuze, and P. Cresswell, “Transport and intracellular distribution of MHC class II molecules and associated invariant chain in normal and antigen-processing mutant cell lines,” *The Journal of Cell Biology*, vol. 125, no. 6, pp. 1225–1237, 1994.

[26] M. Matsumura-Takeda, S. Sogo, Y. Isakari et al., “CD41+/CD45− cells without acetylcholinesterase activity are immature and a major megakaryocytic population in murine bone marrow,” *Stem Cells*, vol. 25, no. 4, pp. 862–870, 2007.

[27] C. Mao, Y. Qiu, H. Sang et al., “Various approaches to modify biomaterial surfaces for improving hemocompatibility,” *Advances in Colloid and Interface Science*, vol. 110, no. 1-2, pp. 5–17, 2004.

[28] M. H. Periayah, A. S. Halim, A. R. Hussein, A. Z. Mat Saad, A. H. Abdul Rashid, and K. Noorsal, “In vitro capacity of different grades of chitosan derivatives to induce platelet adhesion and aggregation,” *International Journal of Biological Macromolecules*, vol. 52, no. 1, pp. 244–249, 2013.

[29] M. H. Kroll and A. I. Schafer, “Biochemical mechanisms of platelet activation,” *Blood*, vol. 74, no. 4, pp. 1181–1195, 1989.

[30] S. J. Shattil, H. Kashiwagi, and N. Pampori, “Integrin signaling: the platelet paradigm,” *Blood*, vol. 91, no. 8, pp. 2645–2657, 1998.

[31] J. C. Reverter, S. Béguin, H. Kessels, R. Kumar, H. C. Hemker, and B. S. Coller, “Inhibition of platelet-mediated, tissue factor-induced thrombin generation by the mouse/human chimeric 7E3 antibody: potential implications for the effect of c7E3 Fab treatment on acute thrombosis and ‘clinical restenosis’,” *Journal of Clinical Investigation*, vol. 98, no. 3, pp. 863–874, 1996.

[32] M. E. I. Badawy and E. I. Rabea, “A biopolymer chitosan and its derivatives as promising antimicrobial agents against plant pathogens and their applications in crop protection,” *International Journal of Carbohydrate Chemistry*, vol. 2011, Article ID 460381, 29 pages, 2011.